Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant

Acute Myeloid Leukemia Clinical Trial

— EXCEL  

Official title:

A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04836390
• Other study ID #: CHLA-20-00314
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: August 24, 2021
• Est. completion date: May 2028

Study information

• Verified date: September 2023
• Source: Children's Hospital Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II pilot study to determine the efficacy of three fixed dose (1 x 108/kg) infusions of ex-vivo expanded human leukocyte antigen (HLA)-haploidentical donor natural killer (NK) cells (haploNK) in children and young adults with high risk acute myeloid leukemia (AML) undergoing HLA-haploidentical hematopoietic cell transplant (haploHCT) with a busulfan and cyclophosphamide-based myeloablative conditioning regimen and post-transplant cyclophosphamide (PTCy) for graft versus host disease (GVHD) prophylaxis. The investigators will also demonstrate the feasibility of performing this trial in a multi-center study.

The investigators hypothesize that the infusion of haploNK in this setting will facilitate immune reconstitution and decrease relapse rates and infectious complications without increasing GVHD, resulting in improved survival as compared to recent historical cohorts of haploHCT without NK cell infusion.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 30
• Est. completion date: May 2028
• Est. primary completion date: May 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 25 Years

Eligibility

Inclusion Criteria:

• Age = 25 years at time of enrollment

• High-risk AML, as defined by one of the following:

• AML in CR1 (defined as <5% blasts in BM by morphology and flow cytometry) having at least one of these high-risk features:

• Mutations associated with high risk disease (Appendix A). Other high-risk features not explicitly stated in Appendix A can be considered after discussion/approval with the protocol chair/team

• MRD-positive at the end of Induction I chemotherapy (defined as flow cytometry = 0.1% blasts)

• AML in =CR2 (defined by <5% blasts in BM by morphology and flow cytometry)

• Recovery from prior cycle of chemotherapy as defined by an absolute neutrophil count = 500/mm3

• AML secondary to select germline marrow failure disorders (with exception of Fanconi Anemia) may be eligible but require approval from Protocol Chairs prior to enrollment.

• Performance status =70% (Lansky for <16 years; Karnofsky for =16 years)

• Adequate major organ system function as demonstrated by:

• Renal: Creatinine clearance (CrCl) =60 mL/min/1.73m2 by Cockcroft-Gault formula, Schwartz formula, or nuclear GFR study (Table 3)

• Hepatic: Total bilirubin <2 mg/dL (unless due to Gilbert syndrome) and ALT and AST < 5x ULN

• Cardiac: LVEF at rest =50% or SF =27% (by MUGA or ECHO)

• Pulmonary: DLCO, FEV1, and FVC = 50% of predicted corrected for hemoglobin. For patients <7 years of age or those unable to perform PFTs: O2 Sat >92% on room air by pulse oximetry and on no supplemental O2 at rest

• The patient, patient's parent, guardian, or legal representative can provide written informed consent

Exclusion Criteria:

• Active extramedullary disease

• Unresolved/ongoing and serious viral, bacterial, or fungal infection despite appropriate treatment

• Positive pregnancy test in a female of child-bearing potential (FCBP)

• Inability to comply with medical therapy or follow-up

• Prior allogeneic transplant

• Patients with Fanconi Anemia and Down syndrome

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
Peripheral blood (PB) = 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).

Locations

Country	Name	City	State
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Ann & Robert H. Lurie Children's Hospital	Chicago	Illinois
United States	Cleveland Clinic Lerner College of Medicine	Cleveland	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	AdventHealth Orlando	Orlando	Florida
United States	Phoenix Children's Hospital	Phoenix	Arizona
United States	Washington University, St. Louis	Saint Louis	Missouri
United States	Johns Hopkins All Children's Hospital	Saint Petersburg	Florida
United States	University of Utah	Salt Lake City	Utah
United States	Fred Hutchinson Cancer Center	Seattle	Washington
United States	New York Medical College	Valhalla	New York

Sponsors (3)

Lead Sponsor	Collaborator
Michael Pulsipher, MD	Nationwide Children's Hospital, Seattle Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1-year RFS	The proportion and corresponding 95% exact binomial CI of patients who are relapse-free at 1-year from day of transplant (Day 0)	1 year
Secondary	Number of functional donor-derived NK cells generated from the device	Product manufacturing failure is defined as inability to generate sufficient NK cell product due to failure to meet release criteria or insufficient cells for at least one full dose (=10^8/NK cells/kg ABW).	2 years
Secondary	GVHD incidence	The incidence of Grade II- IV aGVHD (Day +100) and cGVHD (Day+180, +1 year), opportunistic infections (+1 year), and OS (+1 year and +2 year).	2 years
Secondary	KIR ligand-ligand mismatch	The presence of KIR ligand-ligand mismatch between HLA-haploidentical donor and host and the impact on relapse rate.	2 years
Secondary	Incidence of mixed donor chimerism	Mixed donor chimerism is defined as >5%, but <95%, donor cells detected. Full donor chimerism is defined as >95% donor.	2 years
Secondary	Cumulative incidence of neutrophil engraftment	The cumulative incidence of neutrophil engraftment from the time of transplant will be estimated using the cumulative incidence function with death and relapse prior to engraftment as the competing risk. The definition of neutrophil engraftment is a post-nadir ANC > 500/mm3 for three consecutive laboratory values obtained on different days. The first of the three days will be designated as the day of neutrophil recovery.	2 years
Secondary	Cumulative incidence of platelet engraftment	The cumulative incidence of platelet engraftment from the time of transplant will be estimated using the cumulative incidence function with death and relapse prior to engraftment as the competing risk. The definition of platelet engraftment is sustained platelet count > 20,000/mm3 with no platelet transfusions in the preceding seven days. The first of three consecutive measurements on different days will be designated as the day of initial platelet recovery.	2 years